Nitrogen-containing bisphosphonates and cancer immunotherapy

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Nitrogen-containing bisphosphonates (N-BPs) are standard treatments for bone metastases, primarily inhibiting osteoclast activity and bone resorption.
• Preclinical studies indicate N-BPs possess direct anticancer effects beyond their antiresorptive actions.
• Human gamma-delta (γδ) T cells are crucial immune cells with potent anti-tumor capabilities, bridging innate and adaptive immunity.

Purpose of the Study:

• To review the molecular and cellular mechanisms by which N-BPs enhance the activity of human γδ T cells.
• To explore the potential of N-BPs as agents in cancer immunotherapy by modulating γδ T cell responses.

Main Methods:

• Review of preclinical data on N-BP mechanisms of action.
• Analysis of studies investigating N-BP interactions with human γδ T cells.
• Examination of emerging clinical evidence for N-BPs in cancer immunotherapy.

Main Results:

• N-BPs stimulate the proliferation and cytotoxic functions of human γδ T cells.
• These effects suggest a mechanism for the observed anticancer activity of N-BPs.
• Clinical data are beginning to support the immunotherapeutic potential of N-BPs.

Conclusions:

• N-BPs possess immunomodulatory properties that enhance anti-tumor γδ T cell responses.
• N-BPs represent a promising therapeutic strategy for cancer immunotherapy, leveraging both direct and immune-mediated effects.
• Further clinical investigation is warranted to fully elucidate the role of N-BPs in cancer treatment.